Dallas researchers at FutureSearch Trials are actively recruiting people with obsessive compulsive disorder (OCD) aged 18-65 for a new clinical research study evaluating the safety and efficacy of an investigational treatment in adults. OCD is a mental health disorder that affects one in 100 people and occurs when a person gets caught in a cycle of uncontrollable, reoccurring thoughts and behaviors. This multicenter, placebo controlled, Phase 3 clinical trial is studying adjunctive troriluzole to treat the symptoms of OCD by targeting glutamate. Glutamate is a chemical found in the brain that is believed to be a contributing factor to OCD.
“Alarmingly, it can take up to 14 to 17 years from the onset of symptoms for a person to get an appropriate diagnosis and effective treatment for OCD,” said Michael Downing, board-certified psychiatrist at FutureSearch Trials and investigator in the OCD clinical trial. “Unfortunately, one third of people with OCD do not respond to currently available medications so new therapies are urgently needed. It’s been over two decades since the FDA-approval of a new OCD medication, which is why it is so important for people to participate in clinical trials. We are hopeful troriluzole will help these individuals to better manage their disorder and, in turn, have a better quality of life.”
Clinicians at FutureSearch Trials are now seeking eligible participants for the study. To enroll, participants must be between age 18 and 65, believe they have symptoms of OCD or have been diagnosed with OCD, and not be taking fluvoxamine (Luvox). For more information about participating in the study at FutureSearch Trials call (214) 361-7700 or visit www.ocdtrials.com.
Clinical Trial Details
FutureSearch Trials is one of 113 sites in the U.S. participating in the study. The study is sponsored by New Haven-based Biohaven. The study will enroll approximately 2,000 participants between the ages of 18 and 65 who will receive adjunctive troriluzole or placebo for the treatment of OCD. The efficacy of adjunctive troriluzole compared to placebo will be measured by the Yale-Brown Obsessive Compulsive Scale, a scale designed to rate the severity and type of symptoms in those with the disorder.